Cite
Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain.
MLA
Ribera, Josep-Maria, et al. “Validation of the Burkitt Lymphoma International Prognostic Index in Patients Treated with Two Prospective Chemoimmunotherapy Trials in Spain.” Leukemia & Lymphoma, vol. 63, no. 8, Aug. 2022, pp. 1993–96. EBSCOhost, https://doi.org/10.1080/10428194.2022.2053531.
APA
Ribera, J.-M., García, O., Buendía-Ureña, B., Terol, M.-J., Vicent, A., Vall-Llovera, F., Bergua, J., García-Cadenas, I., Esteve, J., Ribera, J., Acuña-Cruz, E., Herrera, P., Hernández-Rivas, J.-M., Abrisqueta, P., González-Campos, J., Rodríguez, C., Bastos-Oreiro, M., Genescà, E., Caminos, N., & Queipo de Llano, M.-P. (2022). Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. Leukemia & Lymphoma, 63(8), 1993–1996. https://doi.org/10.1080/10428194.2022.2053531
Chicago
Ribera, Josep-Maria, Olga García, Buenaventura Buendía-Ureña, Maria-José Terol, Ana Vicent, Ferran Vall-Llovera, Juan Bergua, et al. 2022. “Validation of the Burkitt Lymphoma International Prognostic Index in Patients Treated with Two Prospective Chemoimmunotherapy Trials in Spain.” Leukemia & Lymphoma 63 (8): 1993–96. doi:10.1080/10428194.2022.2053531.